ЎТКИР МИЕЛОБЛАСТЛИ ЛЕЙКОЗДА ИММУНОФЕНОТИПИК ТЕКШИРИШНИНГ АФЗАЛЛИКЛАРИ
Article Sidebar
Main Article Content
Аннотация:
Ўткир миелобластли лейкозларда иммунофенотипик текширишларни афзалликлари, миелоид қатор хужайраларни синфи ва турини белгилашда кейинги поликимётерапия амалиётини бажаришда, муҳим ҳисобланиб, давлатимизга иқтисодий самарадорликни юзага келишини таъминлашда муҳим ҳисобланади. Аксарият, иммунофенотипик текширувларнинг моҳияти ва иқтисодий самарадорлиги ва ижтимоий аҳамияти ўткир лимфолейкозларда тезкор текшириш амалиётини бажаришда юқори аниқликдаги текшириш усули эканлигини англатади. бу эса, болаларда ўткир миелолейкозлардан ўлим кўрсаткичи камайишининг муҳим мезони ҳисобланади.
Ключевые слова:
Article Details
Как цитировать:
Библиографические ссылки:
Jayavelu AK, Wolf S, Buettner F, Alexe G, The proteogenomic subtypes of acute myeloid leukemia. //Cancer Cell. 2022 Mar 14;40(3):301-317.e12.
Shi X, Feng M, Nakada D. Metabolic dependencies of acute myeloid leukemia stem cells. //Int J Hematol. 2024 May 15.
Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, et al. Frontline treatment of acute myeloid leukemia in adults. //Crit Rev Oncol Hematol. 2017;110:20–34. -
Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia.// Curr Treat Options Oncol. 2020;21(8):66.
Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Summers RJ, Castellino SM, Wechsler DS, Porter CC, Graham DK, Bhasin M. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. //Nat Commun. 2023 Oct 5;14(1):6209.
Abulimiti M, Jia ZY, Wu Y, Yu J, Gong YH, Guan N, Xiong DQ, Ding N, Uddin N, Wang J. Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.// Ann Hematol. 2024 Aug;103(8):2797-2826.
Zhu Y, He J, Li Z, Yang W. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia. //BMC Bioinformatics. 2023 Feb 3;24(1):37.
Ge F, Wang Y, Sharma A, Jaehde U, Essler M, Schmid M, Schmidt-Wolf IGH. Computational analysis of heat shock proteins and ferroptosis-associated lncRNAs to predict prognosis in acute myeloid leukemia patients. //Front Genet. 2023 Aug 1;14:1218276.
Dai Y., Hu L. (2022). HSPB1 overexpression improves hypoxic-ischemic brain damage by attenuating ferroptosis in rats through promoting G6PD expression. //J. Neurophysiol. 128, 1507–1517.
Deng C, Zeng T, Zhu P, Zhao S, Huang Z, Huang W, Zhang W, Huang X, Fu L. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia. //J Cancer Res Clin Oncol. 2023 Sep;149(12):10015-10025.
Lin CC, Hsu YC, Li YH, Kuo YY, Hou HA, Lan KH, Chen TC, Tzeng YS, Kuo YY, Kao CJ, Chuang PH, Tseng MH, Chiu YC, Chou WC, Tien HF. Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia. //Haematologica. 2017 Jun;102(6):1044-1053
Chen C, Chen Z, Chio CL, Zhao Y, Li Y, Liu Z, Jin Z, Wu X, Wei W, Zhao Q, Li Y. Higher Expression of WT1 With Lower CD58 Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia. //Technol Cancer Res Treat. 2021 Jan-Dec;20
Chen TQ, Huang HJ, Zhu SX, Chen XT, Pu KJ, Wang D, An Y, Lian JY, Sun YM, Chen YQ, Wang WT. Blockade of the lncRNA-DOT1L-LAMP5 axis enhances autophagy and promotes degradation of MLL fusion proteins. //Exp Hematol Oncol. 2024 Feb 19;13(1):18.
Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.// Leukemia. 2020 Mar;34(3):735-745.
Duployez N, Marceau-Renaut A, Villenet C, Petit A, Wang JCY, Preudhomme C, Cheok M. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. //Leukemia. 2019 Feb;33(2):348-357.
Ling RE, Cross JW, Roy A. Aberrant stem cell and developmental programs in pediatric leukemia.// Front Cell Dev Biol. 2024 Mar 27;